<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01330940</url>
  </required_header>
  <id_info>
    <org_study_id>1100</org_study_id>
    <nct_id>NCT01330940</nct_id>
  </id_info>
  <brief_title>Effect of Diet Orange Soda on Urinary Lithogenicity</brief_title>
  <official_title>Effect of Diet Orange Soda on Urinary Lithogenicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA New York Harbor Healthcare System</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA New York Harbor Healthcare System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Beverages containing citrate may be useful in increasing urine citrate content and urine pH.
      Such changes in urine chemistry could help prevent kidney stones. Diet orange soda has more
      citrate than other similar beverages. The investigators are interested in whether diet soda
      will improve urine chemistry in the appropriate manner.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The effect of orange soda compared with water in changing 24 hour urine citrate excretion in
      mg/day will be determined.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in urine citrate content</measure>
    <time_frame>1 week</time_frame>
    <description>Citrate is measured in 24h urine sample and expressed as mg/day</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in urine pH</measure>
    <time_frame>One week</time_frame>
    <description>urine pH is measured in a 24h urine sample and has no units</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Kidney Stones</condition>
  <condition>Nephrolithiasis</condition>
  <condition>Urolithiasis</condition>
  <arm_group>
    <arm_group_label>Water drinking</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>32 ounces of water/24 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>orange soda drinking</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>32 ounces orange soda</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Orange soda</intervention_name>
    <description>32 ounces per day</description>
    <arm_group_label>Water drinking</arm_group_label>
    <arm_group_label>orange soda drinking</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-65 years old

          -  able to sign consent

          -  ability to reliably urinate into a vessel and measure urine volume

        Exclusion Criteria:

          -  prior history of nephrolithiasis

          -  a known history of metabolic bone disease

          -  hyperthyroidism

          -  hyperparathyroidism or chronic kidney disease

          -  current use of diuretics

          -  current use of potassium citrate or other oral alkali supplementation and

          -  use of calcium supplementation that could not be stopped
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David S Goldfarb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Harbor VA Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York Harbor VA Medical Center</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2011</study_first_submitted>
  <study_first_submitted_qc>April 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2011</study_first_posted>
  <last_update_submitted>September 6, 2012</last_update_submitted>
  <last_update_submitted_qc>September 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VA New York Harbor Healthcare System</investigator_affiliation>
    <investigator_full_name>David S. Goldfarb, M.D.</investigator_full_name>
    <investigator_title>Chief, Nephrology</investigator_title>
  </responsible_party>
  <keyword>Kidney stones</keyword>
  <keyword>Calcium</keyword>
  <keyword>citrate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
    <mesh_term>Urolithiasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

